In 2023, the FDA finalized its reclassification of several peptide compounds including BPC-157, TB-500 (thymosin beta-4), CJC-1295, ipamorelin, and others removing them from the list of bulk drug substances permitted for compounding under Section 503A and 503B of the Food Drug and Cosmetic Act
No, it is based on preclinical evidence and user practice rather than human clinical trials
They are not approved for human or animal consumption, medical use, or diagnostic purposes
IV infusion (250-500 mg over 2-4 hours) delivers the highest peak levels and is used in clinical settings
Understanding the nuances of research versus pharmaceutical grade peptides and the landscape of grey market peptides provides important context for sourcing decisions
The injectable forms can have less digestive problems than the oral forms